Today's New Biotech Profile (Below) Requires Immediate Attention - Must Read Full Report
Based On This Report, See Why PHBI Could Be Significantly Undervalued While Displaying Staggering Upside Potential
Before today's opening bell, I want you to focus in on what I consider my #1 stock idea in the Biotech and Green Wave sectors:
Your new breakout profile is:
Pharmagreen Biotech Inc. (PHBI)
Pharmagreen is a biotech sciences company with specialized products and services.
Yahoo Finance reports PHBI to currently have 16.1Mn shares in its float meaning volatility could lead to price spiking if above average momentum floods into this profile.
Here's why this could happen...
The Top #1 PHBI Catalyst - New Ground-Breaking Complex
Pharmagreen Selects ICF (Insulated Concrete Forms) Building Technology for the Construction of its [...] Biotech Complex Building Material
CARSON CITY, NV, Jan. 16, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Pharmagreen Biotech, Inc., (OTC: PHBI), is pleased to announce today that it signed a memorandum of understanding with Here to Serve Holding Corp., (OTC:HTSC) to provide consulting services and supply ICF building material (Insulated Concrete Forms) for the construction of Pharmagreen’s 63,000 square foot facility, the [...] Biotech Complex.
The complex, which will take about 18 months to construct, makes use of cutting edge technologies in its engineering, water recycling and conservation techniques, as well as with its construction material resulting in a reduced carbon footprint and secure, uniquely advanced, eco-friendly and semi-automated tissue culture, clean-room laboratory, extraction, distillation and research facility.
Read the full article here.
The biotech complex is projected to provide the annual in-vitro production and supply of over 10 million "Green Wave" tissue cultured plantlets and ready-to-grow starter crops for:
- Licensed commercial grow operations
- Orchard style high CB hemp farms
According to Cesar Herrera, President of Here To Serve Holding Corp, "We believe Pharmagreen's biotech tissue culture complex will be the world's first truly state-of-the-art "Green Wave" facility.
Peter Wojcik, President and CEO of Pharmagreen stated, “We are building our complex to the highest standards in engineering and building materials..."
With PHBI trading in the $.50 range, it could just be a matter of time until traders pay attention to how game-changing this new complex could be for the company.
If that happens, share prices could spike massively in the short-term. $.08 per share may end up looking extremely undervalued.
Here are even more reasons to pay attention to PHBI...
PHBI's Next 3 Catalysts Driving Potential Share Price Growth
Catalyst #1: Pharmagreen Provides Update
CARSON CITY, NV, Dec. 12, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Pharmagreen Biotech, Inc., (OTC PINKS: PHBI), is pleased to provide a company development update. The company has secured significant credit facility to date and plans to use the funds to move forward with its projects development to build a state of the art all year round greenhouse and a tissue cultured starter plantlet production facility. The all year round greenhouse was added to the company’s plans for a first build out as time to complete construction is less than six months and revenue producing within 3 months of operations. The greenhouse will allow the company to earn revenues while the tissue culture facility is under construction.
Here are your 3 main takeaways from this PR snip-it:
No. 1 - PHBI has secured a significant line of credit to push forward its company's growth.
No. 2 - They are moving forward with development on their 24/7/365 production facility.
No. 3 - After completing construction in less than 6 months, it will only take PHBI 3 additional months to start churning out revenues.
Catalyst #2: Pharmagreen Biotech is Seeking to Revolutionize Cancer Research and More with Their Botany Center
The CB industry is worth billions, and is showing no signs of slowing down with many CB related companies now providing crowdfunding investment opp's to both accredited and non-accredited inve*stors who wish to participate in its growth. It may also help discover cures and treatments for cancer. Pharmagreen Biotech, with their S1 document now effective from the SEC, is one such company targeting cancer research and much more with their vision of multi-purpose CB Botany Centers.
Catalyst #3: Pharmagreen Signs a LOI for Supply of CB Dana Hemp Starter Plantlets
Pharmagreen Biotech, Inc. is pleased to announce that its Canadian subsidiary, WFS Pharmagreen Inc., has signed a Letter of Intent with Carpere Inc. for the supply of “CB Dana” hemp starter plantlets for the 2020 farming season and beyond.
The Pharmagreen team is excited to work with Carpere to be their supplier of all female high CB hemp starter plantlets to produce the highest quality high CB flower tops as well as production of the CB whole hemp oils and isolate. Carpere owns and manages farmland, on behalf of farmers, in excess of 100,000 acres throughout Canada.